SET and colorectal carcinoma: We next stratified our cohort by stage; to our surprise, we found that SET overexpression strongly associates with relapse in those CRC patients with stage II at diagnosis (p = 0.008), whereas significance was far from being achieved in the subgroup of CRC patients with stage III disease (p = 0.882) (Table 2).